Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-05-15 @ 5:12 PM
Study NCT ID:
NCT02446093
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-08
First Post:
2015-04-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Sponsor:
Candel Therapeutics, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
PaTK02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |